Cover Image
市場調查報告書

肥胖 - First-in-Class的技術創新的識別與商品化

Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation

出版商 GBI Research 商品編碼 345477
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
肥胖 - First-in-Class的技術創新的識別與商品化 Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation
出版日期: 2015年10月01日 內容資訊: 英文 87 Pages
簡介

肥胖是全世界的健康問題。為了大幅度降低肥胖患者的健康風險,減重改善生活習慣加上使用藥物療法。可是現在可取得的減肥藥由於長期安全性低、減重效果緩慢而有很大限制。

本報告提供全球減肥藥市場相關調查、目前未滿足需求和開發平台趨勢、創新的產品概要、今後預測等彙整資料。

第1章 目錄

第2章 摘要整理

  • 肥胖市場上未滿足需求高
  • 非常創新且多樣的開發平台
  • 交易環境為持續投資的機會

第3章 技術創新案例

  • 生技藥品的機會擴大
  • 分子標的多元化
  • 創新的First-in-Class產品開發的魅力
  • 法律規章,償付政策First-in-Class產品的技術創新
  • 持續的技術創新
  • GBI調查報告指南

第4章 臨床性及商業性環境

  • 疾病概要
  • 病因
  • 病理學
  • 流行病學
  • 分類和診斷
  • 共生病症
  • 預後
  • 治療流程及治療方法
  • 已上市產品概要
  • 目前未滿足需求

第5章 開發中產品的技術創新評估

  • 各分子、各相位、各治療標的開發平台
  • 肥胖市場與各治療標的系列開發平台之間的計劃比較分佈
  • 以新分子標的為目標的First-in-Class開發平台計劃

第6章 信號途徑、遺傳學、技術創新

  • 肥胖的信號網路的複雜度
  • 信號途徑,遺傳的風險因素,First-in-Class分子標的整合
  • First-in-Class標的矩陣評估

第7章 First-in-Class標的評估

第8章 交易與策略性聯合

  • 產業的First-in-Class交易
  • 授權
  • 共同開發
  • 授權或不參與共同開發的First-in-Class計劃

第9章 附錄

目錄
Product Code: GBIHC371MR

Executive Summary

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to improve weight loss in order to significantly reduce obesity-associated health risks in obese patients. However, the use of currently available anti-obesity drugs is largely limited by poor long-term safety and a modest weight loss effect. Despite substantial clinical and regulatory challenges, the early-stage obesity pipeline remains robust, containing a high level of first-in-class innovation that has the potential to be translated into effective and safe weight loss treatments.

Scope

Historically, the obesity market has suffered from long-term safety concerns and modest efficacy with current treatments, both of which contribute to the low prescription rate and limited widespread use.

  • What are the main safety concerns that lead to significant challenges in gaining drug approval in obesity?
  • Why is sustainable weight loss difficult to achieve, and what is the implication for future drug development?

Analysis reveals a high level of innovation and diversity in the pipeline, with 75 first-in-class programs identified to act on 60 unique molecular targets.

  • What is the dominant target family across these first-in-class pipeline products?
  • How well do they align with the underlying signaling pathways governing the central and peripheral regulation of food intake, and energy expenditure?

Some first-in-class targets are deemed more likely to be developed into marketable treatments than others, having demonstrated substantial body weight reduction in Preclinical studies and addressing multiple mechanisms underpinning the development of obesity.

  • What is the scientific rationale behind these targets? How are they likely to surpass existing treatment?
  • Apart from body weight change, what other parameters are commonly used to measure the effect of investigational therapies?

Deals involving first-in-class obesity products are more likely to be made in earlier stages of development than non-first-in-class deals, supported by industry-wide analysis.

  • What is the dominant molecular target in the obesity deals landscape?
  • What are the promising first-in-class products still available for future licensing?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the available treatment options and their limitations in terms of safety and efficacy.
  • Visualize the composition of the obesity market to highlight the current unmet needs in order to gain a competitive understanding of the key opportunities.
  • Analyze the obesity pipeline and stratify by stage of development, molecule type, and molecular target; the diversity of molecular targets in the pipeline is extremely encouraging as obesity is characterized by the complex interplay between central and peripheral mechanisms.
  • Assess the therapeutic potential of first-in-class targets using a proprietary matrix that assesses and ranks first-in-class products according to clinical potential.
  • Target the most promising and innovative obesity products for early-stage investment by analyzing trends in licensing and co-development deals and accessing a curated list of first-in-class therapies potentially open to deal-making opportunities.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. High Unmet Need Remains in the Obesity Market
  • 2.2. Highly Innovative and Diverse Pipeline
  • 2.3. Deals Landscape Presents Substantial Investment Opportunities

3. The Case for Innovation

  • 3.1. Growing Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Developments Remain Attractive
  • 3.4. Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
  • 3.5. Sustained Innovation
  • 3.6. GBI Research Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Disease Overview
  • 4.2. Disease Etiology
    • 4.2.1. Genetics
  • 4.3. Disease Pathophysiology
    • 4.3.1. Central Regulation of Energy Homeostasis
    • 4.3.2. Endocrine Regulation in Energy Balance
    • 4.3.3. Adipose Tissue and Regulation of Energy Expenditure
    • 4.3.4. Dysregulation of Adipokines and Contribution to Obesity and Related Metabolic Disorders
  • 4.4. Epidemiology
  • 4.5. Classification and Diagnosis
  • 4.6. Co-morbidities
    • 4.6.1. Type 2 Diabetes
    • 4.6.2. Hypertension
    • 4.6.3. Dyslipidemia and Cardiovascular Diseases
    • 4.6.4. Respiratory Complications
    • 4.6.5. Osteoarthritis
    • 4.6.6. Cancer Risk
  • 4.7. Prognosis
  • 4.8. Treatment Algorithm and Options
    • 4.8.1. Lifestyle and Behavioral Modification
    • 4.8.2. Bariatric Surgery
    • 4.8.3. Pharmacotherapy
  • 4.9. Overview of Marketed Products
    • 4.9.1. Molecule Type and Target Analysis
    • 4.9.2. Major Drug Withdrawals in the Obesity Market
    • 4.9.3. Significant Challenges with Reimbursement in the Obesity Market
  • 4.10. Current Unmet Needs

5. Assessment of Pipeline Product Innovation

  • 5.1. Obesity Pipeline by Molecule Type, Phase and Therapeutic Target
  • 5.2. Comparative Distribution of Programs between Obesity Market and Pipeline by Therapeutic Target Family
  • 5.3. First-in-Class Pipeline Programs Targeting Novel Molecular Targets

6. Signaling Pathways, Genetics and Innovation Alignment

  • 6.1. The Complexity of Signaling Networks in Obesity
  • 6.2. Signaling Pathways, Genetic Risk Factors and First-in-Class Molecular Target Integration
  • 6.3. First-in-Class Target Matrix Assessment

7. First-in-Class Target Evaluation

  • 7.1. Pipeline Programs Targeting Growth Hormone Secretagogue Receptor 1a and Ghrelin
  • 7.2. Pipeline Programs Targeting Neuropeptide Y Receptor 2
  • 7.3. Pipeline Programs Targeting Neuropeptide Y Receptor 1
  • 7.4. Pipeline Programs Targeting Adipocyte Fatty Acid Binding Protein 4
  • 7.5. Pipeline Programs Targeting Sterol Regulatory Element-Binding Protein 1 and 2
  • 7.6. Pipeline Programs Targeting Glycoprotein 130 Receptor
  • 7.7. Pipeline Programs Targeting Bombesin Receptor Subtype 3
  • 7.8. Pipeline Programs Targeting Acetyl-CoA Carboxylase 1 and 2
  • 7.9. Pipeline Programs Targeting Stearoyl-CoA Desaturase 1
  • 7.10. Pipeline Programs Targeting Bone Morphogenetic Protein-7
  • 7.11. Conclusion

8. Deals and Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Licensing Deals
  • 8.3. Co-development Deals
  • 8.4. First-in-Class Programs Not Involved in Licensing or Co-Development Deals

9. Appendix

  • 9.1. Abbreviations
  • 9.2. References
  • 9.3. Methodology
  • 9.4. Secondary Research
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: The International Classification of Underweight, Overweight and Obesity in Adults
  • Table 2: Treatment Options Dependent on Body Mass Index

List of Figures

  • Figure 1: Innovation Trends in Product Approvals, 1987-2013
  • Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
  • Figure 3: Molecular Targets of Marketed Products, 2015
  • Figure 4: Developmental Pipeline Overview
  • Figure 5: Players in the Obesity Pipeline
  • Figure 6: Developmental Pipeline Overview
  • Figure 7: Molecular Target Category Comparison, Pipeline and Marketed Products
  • Figure 8: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular Targets
  • Figure 9: Obesity, Global, First-in-Class Pipeline Products
  • Figure 10: Signaling Networks of Functional Families in Obesity
  • Figure 11: Location of Key First-in-Class Targets within the Signaling Matrix
  • Figure 12: First-in-Class Molecular Target Analysis Matrix
  • Figure 13: Data and Evidence for Growth Hormone Secretagogue Receptor 1a as a Therapeutic Target
  • Figure 14: Pipeline Programs Targeting Growth Hormone Secretagogue Receptor 1a and Ghrelin
  • Figure 15: Data and Evidence for Neuropeptide Y Receptor 2 as a Therapeutic Target
  • Figure 16: Pipeline Programs Targeting Neuropeptide Y Receptor 2
  • Figure 17: Data and Evidence for Neuropeptide Y Receptor 1 as a Therapeutic Target
  • Figure 18: Pipeline Programs Targeting Neuropeptide Y Receptor 1
  • Figure 19: Data and Evidence for Adipocyte Fatty Acid Binding Protein 4as a Therapeutic Target
  • Figure 20: Pipeline Programs Targeting Adipocyte Fatty Acid Binding Protein 4
  • Figure 21: Data and Evidence for Sterol Regulatory Element-Binding Protein 1 and 2 as a Therapeutic Target
  • Figure 22: Pipeline Programs Targeting Sterol Regulatory Element-Binding Protein 1 and 2
  • Figure 23: Data and Evidence for Glycoprotein 130 Receptor as a Therapeutic Target
  • Figure 24: Pipeline Programs Targeting Glycoprotein 130 Receptor
  • Figure 25: Data and Evidence for Bombesin Receptor Subtype 3 as a Therapeutic Target
  • Figure 26: Pipeline Programs Targeting Bombesin Receptor Subtype 3
  • Figure 27: Data and Evidence for Acetyl-CoA Carboxylase 1 and 2 as a Therapeutic Target
  • Figure 28: Pipeline Programs Targeting Acetyl-CoA Carboxylase 1 and 2
  • Figure 29: Data and Evidence for Stearoyl-CoA Desaturase 1 as a Therapeutic Target
  • Figure 30: Pipeline Programs Targeting Stearoyl-CoA Desaturase 1
  • Figure 31: Data and Evidence for Bone Morphogenetic Protein-7 as a Therapeutic Target
  • Figure 32: Pipeline Programs Targeting Bone Morphogenetic Protein-7
  • Figure 33: Industry-Wide Deals by Stage of Development, 2006-2014
  • Figure 34: Industry-Wide Deals by Stage of Development, 2006-2014
  • Figure 35: Licensing Deals in Obesity, 2006-2015
  • Figure 36: Licensing Deals, Global Distribution, 2006-2015
  • Figure 37: Licensing Deals by Molecule Type and Value, 2006-2015
  • Figure 38: Licensing Deals by Molecular Target, 2006-2015
  • Figure 39: Summary of Licensing Deals in Obesity, 2006-2015
  • Figure 40: Co-development Deals in Obesity, 2006-2015
  • Figure 41: Co-development Deals Global Distribution, 2006-2015
  • Figure 42: Co-development Deals by Molecule Type, 2006-2015
  • Figure 43: Co-development Deals by Molecular Target, 2006-2015
  • Figure 44: Summary of Co-Development Deals in Obesity, 2006-2015
  • Figure 45: First-in-Class Programs with No Recorded Prior Deal Involvement, 2006-2015
Back to Top